Loading stock data…
KAPA
$0.46-0.02 (-4.33%)
Market ClosedLast close May 13
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
KAPA in the Healthcare sector is trading at $0.46. Wall Street consensus targets $8.33 (3 analysts), implying a +1696.0% move over the next 12 months. The stock is currently near its 52-week low of $0.40, remaining 47.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 8 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1696.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 8) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$0.46
Potential Downside
0%
Whystock Fair Value$0.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.90%
Volume
Today's trading volume
454,827
Recent News
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
The trial consisted of subjects who had not responded to at least one form of hormone therapy previously.
Top Midday Gainers
Longevity Health (XAGE) shares almost doubled amid heavy trading after the company said late Monday